HighCape Partners Closes Initial $80 Million Growth Equity Fund
BALTIMORE, Maryland, September 16, 2015 – HighCape Partners Management, L.P. today announced the final closing of HighCape Partners, L.P., its initial $80 million growth equity fund focused on investing in commercial-stage life sciences companies.
HighCape Partners intends to invest in six to eight life sciences companies that are in the early revenue or product launch stage and have a superior product that delivers value to the healthcare system and has a clear path to commercialization.
The Partnership’s investment thesis is led by co-founders, Kevin Rakin and Matt Zuga, and actively supported by a multidisciplinary team of Operating Partners, including Jennifer Barretta, Charles Hart, PhD, Carol Reed, MD, and Dean Tozer.
“We are committed to developing a focused and specialized portfolio because we expect to play an active role in shaping each portfolio company’s commercial strategy,” said Mr. Rakin, who has a highly successful track record in acquiring strategic assets and developing and implementing growth plans. “We excel when we have the opportunity to assist management teams in executing on an agreed upon path to growth.”
The Partnership is currently invested in two companies: Cheetah Medical, a leader in non-invasive cardiac output and hemodynamic monitoring, and TELA Bio, a surgical reconstruction company committed to collaborating with surgeons to understand and address the unmet clinical needs in soft tissue repair.
“HighCape Partners is dedicated to generating strong financial returns for our limited partners and takes a hands-on approach to identifying portfolio companies that we believe can benefit from an active collaboration with Kevin and myself, as well as our Operating Partners,” said Mr. Zuga, who has extensive investment and finance experience in the life sciences sector. “Many companies have difficulty transitioning from the product development stage to the commercialization stage and we believe HighCape Partners is uniquely positioned to leverage our collective experience to truly add value to our portfolio companies, thereby achieving a higher probability of success.”
About HighCape Partners
HighCape Partners is a growth equity fund that invests in commercial-stage life sciences companies. The Company applies decades of combined investment and operational experience to help transform its portfolio companies into sustainable businesses with multiple exit alternatives. For more information, visit highcape.com.
Could HighCape be the right partner for your growing business?
Contact us for more information.
452 5th Ave, 21st Floor
New York, NY 10018